| Literature DB >> 31001551 |
Achraf Laghmich1, Fatima Zahra Alaoui Ismaili1, Amina Barakat1, Naima Ghailani Nourouti1, Mohamed Khattab2, Mohcine Bennani Mechita1.
Abstract
Unlike the other hemoglobinopathies, few researches have been published concerning α-thalassemia in Morocco. The epidemiological features and the mutation spectrum of this disease are still unknown. This regional newborn screening is the first to study α-thalassemia in the north of Morocco. During the period from January 2015 to December 2016, 1658 newborns umbilical blood samples were investigated. Suspected newborns were screened for α-globin defects using Gap-PCR and Multiplex Ligation-dependent Probe Amplification technique. The prevalence of α-thalassemia, its mutation spectrum, and its allelic frequencies were described for the first time in Morocco. Six different α-globin genetic disorders were detected in 16 neonates. This screening valued the prevalence of α-thalassemia in the studied population at 0.96% and showed the wide mutation spectrum and the heterogeneous geographical distribution of the disease. A high rate of carriers was observed in Laouamra, a rural commune in Larache province. Heterogeneity of α-globin alleles in Morocco explains the high variability of α-thalassemia severity. This diversity reflects the anthropological history of the country. These results would contribute to the prevention of thalassemia in Morocco directing the design of a nationwide screening strategy and awareness campaign.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31001551 PMCID: PMC6436373 DOI: 10.1155/2019/2080352
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Geographic location of the region concerned by the study.
Complete Blood Count and ferritin profile in the north of Morocco.
| Province | population | Anemic | Non Anemic | Microcytic hypochromic anemia | Other anemia | Ferritin level | ||
|---|---|---|---|---|---|---|---|---|
| Low | Normal | High | ||||||
| Tangier, Assilah-Fahs-Anjra | 633 | 163 | 470 | 79 | 84 | 52 | 11 | 16 |
|
| ||||||||
| Tetouan, M'diq, Fnideq | 483 | 109 | 374 | 66 | 43 | 46 | 5 | 15 |
|
| ||||||||
| Larache | 542 | 169 | 373 | 119 | 50 | 75 | 9 | 35 |
∗ means other anemia: macrocytic normochromic, macrocytic hypochromic, normocytic normochromic, and normocytic hypochromic.
Mutations and their allelic frequencies in the studied region.
| Molecular defect | Allele frequencies (%) | Genotypes | N |
|---|---|---|---|
| - | 0.33 | - | 6 |
| - | 1 | ||
| - | 2 | ||
|
| |||
| - | 0.12 | - | 2 |
| - | 1 | ||
|
| |||
| - | 0.06 | - | 2 |
|
| |||
| HS-40 | 0.03 |
| 1 |
|
| |||
| - | 0.03 | - | 1 |
Hematologic features and hemoglobin Bart's levels by genotype.
| Genotype | Province | Hb | MCV | MCH | Hb Bart's | ||
|---|---|---|---|---|---|---|---|
| Tangier Assilah Fahs-Anjra | Tetouan M'diq Fnideq | Larache | |||||
| - | 2 | 1 | 3 | 11.5 | 126.2 | 35.4 | 0.8 |
| 13.1 | 92.6 | 29.2 | 0 | ||||
| 13.5 | 94.7 | 29.9 | 1.8 | ||||
| 12.5 | 92.5 | 28.7 | 0.45 | ||||
| 15.5 | 93.5 | 29.6 | 0.9 | ||||
| 12.5 | 94 | 33.8 | 0 | ||||
|
| |||||||
| - | 0 | 0 | 2 | 11.1 | 95.9 | 29.9 | 1.8 |
| 13.3 | 98.5 | 31.5 | 2.3 | ||||
|
| |||||||
| - | 0 | 0 | 1 | 11.8 | 96.3 | 30.3 | 1.3 |
|
| |||||||
|
| 1 | 0 | 1 | 11.2 | 93.3 | 28.5 | 0 |
| 11.4 | 93.7 | 28.9 | 0 | ||||
|
| |||||||
| - | 0 | 0 | 2 | 11.9 | 95.6 | 28.3 | 0.4 |
| 13.2 | 91 | 31.9 | 1 | ||||
|
| |||||||
| - | 0 | 1 | 0 | 12.7 | 92.7 | 29.9 | 3 |
|
| |||||||
|
| 0 | 0 | 1 | 11.2 | 92.4 | 29.8 | 1.1 |
|
| |||||||
| - | 0 | 0 | 1 | 12.1 | 88.5 | 29.5 | 5.2 |
Hb: hemoglobin, MCV: mean corpuscular volume, MCH: mean corpuscular hemoglobin.
Figure 2Multiplex Ligation-dependent Probe Amplification results. (a) Heterozygous deletion α3.7; (b) homozygous deletion α3.7; (c) homozygous deletion α3.7 with ζ deletion in cis; (d) αααanti 3.7 deletion; (e) heterozygous deletion α4.2; (f) homozygous deletion α4.2; (g) HS-40 deletion; (h) - -MED-I deletion; (i) African polymorphism.